ARTICLE | Company News
Millennium, Trigen Holdings AG deal
January 29, 2007 8:00 AM UTC
Trigen received exclusive worldwide rights to develop and commercialize MLNM's IP covering glycoprotein VI ( GPVI), a platelet collagen receptor involved in thrombosis. Trigen expects to complete Phas...